1-5 of 5
Dimple A. Modi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Clinical Trials & Observations
Stephen K. Tahir, Emiliano Calvo, Benedito A. Carneiro, Junichiro Yuda, Aditya Shreenivas, Mojca Jongen-Lavrencic, Eelke Gort, Kenichi Ishizawa, Daniel Morillo, Carla Biesdorf, Morey Smith, Dong Cheng, Monica Motwani, David Sharon, Tamar Uziel, Dimple A. Modi, Fritz G. Buchanan, Susan Morgan-Lappe, Bruno C. Medeiros, Darren C. Phillips
Journal: Blood
Blood (2023) 141 (17): 2114–2126.
https://doi.org/10.1182/blood.2022017333
Published: 2023
Includes: Supplemental data
Journal Articles

Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis

John Mascarenhas, MD, Rabih Saab, PhD, Deanna Brackman, PhD, Dimple A. Modi, PhD, Linu Abraham, PhD, James E. Ward, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-137686
Published: 2020
Journal Articles

Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma

Ariosto Siqueira Silva, PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Maria D Coelho Siqueira Silva, MSc, Praneeth Reddy Sudalagunta, PhD, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Melissa Mitchell, Hongyue Dai, Qi Zhang, PhD, Oliver Hampton, Xin Lu, Dimple A. Modi, PhD, Monica Motwani, PhD, Jason Harb, PhD, Jeremy A. Ross, Kenneth H. Shain, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–50.
https://doi.org/10.1182/blood-2020-134924
Published: 2020
Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 539.
https://doi.org/10.1182/blood-2019-126854
Published: 2019
Journal Articles

First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)

Maja J.A. de Jonge, MD, Benedito A. Carneiro, MD, Lot Devriese, MD PhD, Toshihiko Doi, MD PhD, Sudhir Penugonda, MD MPH, Adam M. Petrich, MD, Silpa Nuthalapati, PhD, Monica Motwani, PhD, Dimple A. Modi, PhD, Yu-Wei Chang, PhD, Emiliano Calvo, MD PhD, Victor Moreno, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3924.
https://doi.org/10.1182/blood-2019-129783
Published: 2019